The targeting of GITR by an agonistic antibody in patients with advanced cancer and in mice with advanced tumors demonstrated that GITR agonism promotes effector T cell functions and hampers suppression by circulating and intra-tumoral regulatory T cells [105]. The gene discussed is TNFRSF18; the disease is cancer.